Sarepta Signs a Research Agreement with the US Department of Defense to Identify Antisense Oligonucleotides Against COVID-19
Shots:
- Sarepta and USAMRIID have entered into a CRADA to jointly identify antisense oligonucleotides utilizing Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform with activity against SARS-CoV-2 for the potential treatment of COVID-19
- Sarepta will design- synthesize and manufacture multiple peptide-conjugated PMO (PPMO) constructs based on genetic sequencing of SARS-CoV-2 while USAMRIID will assess the constructs on characterized wild-type SARS-CoV-2 viruses for their potential to inhibit viral infection
- Following the results- Sarepta and USAMRIID will contemplate collaborative funding proposals to advance the development of treatments against COVID-19
Click here to read full press release/ article | Ref: Sarepta | Image: Sarepta
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
